Rechallenge of IO/TKI in Second-Line After IO/TKI in First-Line Will Not Add Any Benefits
New evidence suggests no benefit in adding immune checkpoint inhibitors to cabozantinib for patients with metastatic renal cell carcinoma who have progressed after prior immune checkpoint inhibitors therapy.
